{"task_id": "80fdcc142705f883", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 65/464)", "text": "TION\nCLINICAL FEATURES (CONT\u2019D)\n50\nMitral Stenosis\n\n--- Page 72 ---\nDIAGNOSTIC AND PROGNOSTIC ISSUES\nMITRAL VALVE AREA AND SEVERITY\n\u0002\nNORMAL = 4 5 cm2\n\u0002\nMILD = 1.5 2.5 cm2 or mean gradient <5 mmHg\n\u0002\nMODERATE\n=\n1 1.5\ncm2\nor\nmean\ngradient\n5 10 mmHg\n\u0002\nSEVERE = <1 cm2 or mean gradient >10 mmHg\n\u0002\nSYMPTOMS\nusually do not appear until valve\n<2.0 cm2. Symptoms at rest appear when valve\n<1.5 cm2. Onset of symptoms usually precipitated\nby exercise, emotional stress, infection, pregnancy,\nor rapid atrial fibrillation\nPROGRESSION\n\b0.1 0.3 cm2/year. Initially slow\nstable course (latent period) of 20 40 years between\nrheumatic fever and symptoms. From onset of symp\ntoms (accelerated period), around 10 years until dis\nability. Overall 10 year survival is 50 60% in untreated\nsymptomatic MS, >80% in asymptomatic. Median\nsurvival <3 years with severe pulmonary hypertension\nMANAGEMENT\nLIFESTYLE CHANGES\nsalt restriction/diuretics\nMEDICATIONS\nnegative chronotropic agents to pro\nlong diastolic filling (b blockers, non dihydropyridine\ncalcium channel blockers). Anticoagulation for patients\nwith concomitant atrial fibrillation, left atrial thrombus,\nor prior embolic event (even if in sinus rhythm). Pro\nphylaxis for rheumatic fever (secondary prevention)\nFOLLOW UP\nany change in symptoms warrant re\nevaluation and echocardiogram. Otherwise, yearly\nevaluation in asymptomatic patients including CXR\nand ECG. Yearly echocardiogram for severe MS\nPROCEDURES\nindicated when symptomatic severe\nmitral stenosis. Percutaneous balloon mitral valvu\nloplasty (particularly for patients with non calcified\nmitral valve, mild mitral regurgitation, and no other\ncardiac interventions) is equivalent to surgical val\nvuloplasty in terms of success. Average increase in\nvalve area is 1.0 cm2\nSPECIFIC ENTITIES\nACUTE RHEUMATIC FEVER AND RHEUMATIC\nHEART DISEASE\n\u0002\nPATHOPHYSIOLOGY\ngroup A Streptococcus infec\ntion ! non suppurative inflammation with car\ndiac, joints, and CNS manifestations 2 4 weeks\nlater. Post Streptococcus glomerulonephritis and\nscarlet fever may also occur separately as compli\ncations of group A Streptococcus infection\n\u0002\nJONES CRITERIA FOR ACUTE RHEUMATIC FEVER\n\u0002\nMAJOR CRITERIA wJ'NESw\n\u0002 JOINT-MIGRATORY POLYARTHRITIS\n\u0002 'CARDITIS (pericarditis, myocarditis, valvulitis)\n\u0002 NODULES (subcutaneous)\n\u0002 ERYTHEMA MARGINATUM\n\u0002 SYDENHAM CHOREA\n\u0002\nMINOR CRITERIA\nclinical (fever, polyarthralgias),\nlaboratory (\" ESR, prolonged PR interval)\n\u0002\nDIAGNOSIS\neither two major criteria or one\nmajor criterion and two minor criteria, plus evi\ndence of antecedent streptococcal infection (e.g.\npositive throat culture or rapid antigen detection\ntest or elevated streptococcal antibody test)\n\u0002\nINVESTIGATIONS\nanti Streptolysin\nO\nantibodies,\nanti DNase B, antihyaluronidase, positive throat\nculture, echocardiogram\n\u0002\nTREATMENTS\npatients with rheumatic disease are\nat high risk of recurrent rheumatic fever. Recurrent\ndisease causes additional valve damage, and thus\nthese patients should receive prophylaxis for rheu\nmatic fever (penicillin G 1.2 M U IM q4weeks, peni\ncillin V 250 mg PO BID, or erythromycin 250 mg PO\nBID if allergic to penicillin). For patients with valve\ninvolvement, therapy should continue for at least 10\nyears after the last episode of rheumatic fever and\nto at least age 40. With a history of carditis in the\nabsence of persistent valvular disease, treat for 10\nyears or until age 21 (whichever is longer)\nMitral Regurgitation\nACC/AHA 2008 Guidelines\nDIFFERENTIAL DIAGNOSIS\nVALVE ABNORMALITY\nrheumatic heart disease,\ninfective endocarditis, mitral valve prolapse, myx\nomatous degeneration, mitral annular calcification,\nruptured chordae tendineae, drugs (fenfluramine)\nLEFT VENTRICULAR DILATATION\nmyocardial\ninfarction, dilated cardiomyopathy\nPATHOPHYSIOLOGY\nLEAKY MITRAL VALVE\nleft atrial and ventricle\nvolume overload ! atrial fibrillation and left heart\nfailure\nCLINICAL FEATURES\nCLINICAL FEATURES\nexertional dyspnea, fatigue,\ndecreased S1, widely split S2, S3, holosystolic murmur\n(over apex), displaced apex\nINVESTIGATIONS\nBASIC\n\u0002 CXR\ncardiomegaly, LAE\n\u0002\nECHOCARDIOGRAM\n\u0002 ECG\nP mitrale, LVH\nSPECIAL\n\u0002\nCARDIAC CATHETERIZATION\nMitral Regurgitation\n51", "text_length": 4154, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 65/464)", "type": "chunk", "chunk_index": 64, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.324989", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.325681", "status": "complete", "chunks_added": 3}